For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Sugen Incorporated

USPTO Granted Patents = 157

% Expired Patents = 33.1

CIPO Patents = 5

EPO Patents = 7

Forward Citations = 3,491

Loading Chart...

Loading Chart...

127 inventors (with patents filed for the assignee):

Peng Cho Tang (101 out of 118 patents)

Gerald McMahon (60 out of 65 patents)

Li Hsiang Sun (47 out of 94 patents)

4. Gregory D Plowman (19 out of 44 patents)

5. Klaus Peter Hirth (19 out of 22 patents)

6. Chung Chen Wei (17 out of 21 patents)

7. Laura Kay Shawver (17 out of 21 patents)

8. Congxin Liang (15 out of 42 patents)

9. Asaad S Nematalla (13 out of 15 patents)

10. Jingrong Jean Cui (12 out of 45 patents)

11. Aviv Gazit (10 out of 30 patents)

12. G Davis Harris, Jr (8 out of 12 patents)

13. Ping Huang (8 out of 16 patents)

14. Tomas Vojkovsky (8 out of 12 patents)

15. Marcel Koenig (8 out of 15 patents)

Core Competencies:

Protein Kinase

Indolinone Derivatives

Biomarkers

Cancer Treatment

Assays

Therapeutic Uses

Cyclooxygenase Inhibitors

Tyrosine Kinase

Phosphatase Inhibitors

Aminoheteroaryl Compounds

Prodrugs

Combinatorial Libraries

157 patents: Sort by Forward Citations

1. 7871786 - GEF-H1b: biomarkers, complexes, assays and therapeutic uses thereof (2011-01-18),

2. 7582756 - 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors (2009-09-01),

3. 7572924 - Pyrrole substituted 2-indolinone protein kinase inhibitors (2009-08-11),

4. 7439329 - GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof (2008-10-21),

5. 7320996 - Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer (2008-01-22),

6. 7256189 - 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors (2007-08-14),

7. 7250417 - Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors (2007-07-31),

8. 7230098 - Aminoheteroaryl compounds as protein kinase inhibitors (2007-06-12),

9. 7217737 - Method and compositions for inhibiting cell proliferative disorders (2007-05-15),

10. 7214700 - (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors (2007-05-08),

11. 7211600 - [object Object] (2007-05-01),

12. 7202265 - Indolinone combinatorial libraries and related products and methods for the treatment of disease (2007-04-10),

13. 7189721 - Bicyclic protein kinase inhibitors (2007-03-13),

14. 7186832 - Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors (2007-03-06),

15. 7186716 - 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors (2007-03-06),

Company Overview

Sugen Incorporated, based in South San Francisco, specializes in the development of innovative protein kinase inhibitors aimed at advancing cancer treatment. The company focuses on the research and application of indolinone derivatives and biomarkers to enhance therapeutic efficacy. With a strong emphasis on assays and therapeutic uses, Sugen is at the forefront of creating targeted therapies that address various oncological challenges. Their expertise extends to cyclooxygenase inhibitors and tyrosine kinase, positioning them as a key player in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

157 Patents

#11 in South San Francisco, CA

#549 in California

#2,522 in US

#5,226 in the World

South San Francisco, CA, United States of America

Sugen Incorporated

Forward Citations = 3,491

127 inventors:

Peng Cho Tang (101 out of 118 patents)

Gerald McMahon (60 out of 65 patents)

Li Hsiang Sun (47 out of 94 patents)

4. Gregory D Plowman (19 out of 44 patents)

5. Klaus Peter Hirth (19 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sugen Incorporated. Retrieved from https://idiyas.com/company/sugen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…